Navigation Links
Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease
Date:10/19/2010

SAN DIEGO, Oct. 19 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).

The launch of Phase 2 follows a fully enrolled Phase 1 portion that demonstrated early safety using an enhanced CERE-120 dosing regimen targeting the substantia nigra and putamen, two brain areas especially affected by Parkinson's disease. This study is enrolling at 11 major medical centers throughout the United States and includes investigators Drs. Mark Stacy and Dennis Turner at Duke University School of Medicine, Drs. Catherine Cho and Ron Alterman at Mount Sinai Medical Center, New York, and Drs. Stewart Factor and Nicholas Boulis at Emory University Hospital, who were all involved in treating the patients in the Phase 1 portion of this study.

Additional clinical sites include Columbia University Medical Center, NYC, NY; Beth Israel Medical Center, NYC, NY; University of Pennsylvania Hospital, Philadelphia, PA; University of Alabama, Birmingham, AL; Rush University Medical Center, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, San Francisco, CA and Stanford University School of Medicine, Palo Alto, CA.

Details on the clinical study can be found at www.ceregene.com or www.clinicaltrials.gov/ct2/show/NCT00985517.

This Phase 2b clinical study is partially funded by a $2.5M LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) award from The Michael J. Fox Foundation for Parkinson's Re
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinsons Disease
2. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
3. Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
4. Echo Therapeutics Initiates Needle-Free Biosensor Program for Continuous Lactate Monitoring
5. LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
6. ISTA Pharmaceuticals Initiates Phase 3 Clinical Program for REMURA™ in Dry Eye Disease
7. N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
8. Vanda Pharmaceuticals Initiates Phase III Clinical Study Aimed at Resetting the Body Clock
9. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
10. Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
11. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 28, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Cardiovascular Drug Delivery ... offering. Drug delivery to the cardiovascular ... because of the anatomy and physiology of the ... all organs of the body. Drugs can be ...
(Date:5/29/2015)... and BOSTON , May ... in instrument development, custom automation, and contract manufacturing, and ... the Nanopatch™ needle-free drug delivery technology, have been named ... of the Nanopatch Jet Coating Instrument , an ... research and product development.  The award was announced last ...
(Date:5/29/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the ... commercializing proven cancer therapies in new orphan drug ... American Association of Cancer Research (AACR) Advances in ... for its lead product candidate VAL-083 ...
Breaking Medicine Technology:Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 3Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5
... VILLAGE, Nev., Nov. 2 PDL BioPharma, Inc. (PDL) ... on its previously disclosed $300 million securitization transaction intended ... royalties. Morgan Stanley & Co. Incorporated acted as ... terms of the securitization transaction, PDL sold to QHP ...
... Nov. 2 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... 30, 2009 on Monday, November 9, 2009, following the close of ... conference call at 5:00 p.m. Eastern Time on the same day ... call will be available for two weeks following the event. ...
Cached Medicine Technology:PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction 2Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009 2Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009 3
(Date:5/30/2015)... (PRWEB) May 30, 2015 AVT, the ... quality assurance, is joining forces with leading proofing solutions ... to the worldwide printing market. , Under ... new software engine for its offline inspection solutions, which ... printing industry and its varying production workflow setups and ...
(Date:5/30/2015)... 30, 2015 The results of a ... has a high potential to cause mesothelioma, regardless of ... now on the Surviving Mesothelioma website. , ... Medicine in Lodz, Poland found that, among the 138 ... 1970 and 2012, all of them happened at plants ...
(Date:5/30/2015)... May 30, 2015 EHO offers a ... Portal that gives hospices the ability to manage their ... of this business model, EHO has been able to ... to its clients and survive among the giants of ... management systems three years ago, it has simplified the ...
(Date:5/30/2015)... 30, 2015 Cyclist Barry Haarde ... for the World 2015: Piles of Miles” near ... awareness about hemophilia and encourage individuals to support ... , Save One Life supports nearly 1,200 impoverished ... countries through direct sponsorships, scholarships and micro-enterprise grants. ...
(Date:5/30/2015)... 30, 2015 This year the ... Pulmonary Horizons to offer one of the most diverse ... discuss successful practices to diagnose, treat and manage patients ... Pulmonary Horizons Conference is Interaction with Multidisciplinary Healthcare ... Overall Needs of Patients with COPD," said Brian W. ...
Breaking Medicine News(10 mins):Health News:AVT and Global Vision Collaborate to Offer Cutting-edge Offline Inspection Solutions for Printing Industry 2Health News:AVT and Global Vision Collaborate to Offer Cutting-edge Offline Inspection Solutions for Printing Industry 3Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 3
... culture than nonaccredited facilities, according to a new study ... Joint Commission Journal on Quality and Patient Safety . ... more than 4,000 facilities across the U.S. identify Joint ... issues such as staffing, teamwork, training, nonpunitive responses to ...
... 27 (HealthDay News) -- Two genetic variations are linked to ... according to new research. Glaucoma affects about 2.2 million ... said in a news release. "Loss of vision from ... irreversible damage to the optic nerve," noted one expert, Dr. ...
... , FRIDAY, April 27 (HealthDay News) -- Electrocardiograph ... risk for sudden cardiac death, according to a new study. ... conducted EKGs on 586 of them based on medical history, ... were found to have a heart disorder known to cause ...
... , THURSDAY, April 26 (HealthDay News) -- Medicare, the federal ... hurtling toward the critical list, but most people don,t want ... new Harris Interactive/HealthDay poll finds. Eighty-three ... Medicare affordable and sustainable, and 51 percent think that "a ...
... , FRIDAY, April 27 (HealthDay News) -- Children who are ... the time they are 12 years old, according to a new ... and the United Kingdom said its findings, published online April 27 ... risk for this type of behavior. Examples of self-harming ...
... from the Research Institute of Wildlife Ecology (FIWI) of ... analysed a capture-recapture data set on common dormice ( ... this species. These small rodents are about the size ... ), but, unlike their rodent cousins, they hibernate ...
Cached Medicine News:Health News:NYUCN's Dr. Laura Wagner: Study finds accreditation improves safety culture at nursing homes 2Health News:Research Gets Closer to Genetic Roots of Glaucoma 2Health News:Heart Test Spots Sudden Death Risk in Young Athletes 2Health News:Americans Support Medicare Reform, But Not on Their Dime: Poll 2Health News:Americans Support Medicare Reform, But Not on Their Dime: Poll 3Health News:Americans Support Medicare Reform, But Not on Their Dime: Poll 4Health News:Bullied Children at Greater Risk for Self-Harm, Study Finds 2Health News:When to have kids: A complex question for hazel dormice 2
Spurling-Kerrison (Colclough) Laminectomie Rongeur. 15 cm - 6, thick footplate, large handle, 40 up-cutting, jaws 3 mm wide....
Kerrison (Micro) Laminectomie Rongeur, with ejector. 18 cm - 7 1/8, with thick footplate, small handle, 90 up-cutting, jaws 2 mm wide....
... The Tangent Posterior Impacted Instrument Set offers ... of the advantages offered by the Tangent ... preparation and the ability to reproduce the ... to ensure proper vertebral body distraction. A ...
Regulates physiological flow within normal ranges of Intraventricular Pressure (IVP) in the supine, sitting or standing position....
Medicine Products: